Instructions Tivortin aspartate oral solution bottle 100 ml
Composition
active ingredient: 1 ml of solution contains L-arginine aspartate 200 mg;
excipients: sorbitol (E 420), sodium saccharin (E 954), methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), food flavoring "Caramel", water for injections.
Dosage form
Oral solution.
Main physicochemical properties: slightly yellowish liquid with a caramel odor.
Pharmacotherapeutic group
Other cardiological drugs. Amino acids.
ATX code C01E.
Pharmacological properties
Pharmacodynamics
Tivortin® aspartate has antihypoxic, cytoprotective, antioxidant, detoxification, membrane-stabilizing effects. It plays an important role in the processes of ammonia neutralization and stimulation of its excretion from the body, enhances the detoxification function of the liver. It has a hepatoprotective effect, positively affects the processes of energy supply in hepatocytes.
As a nitric oxide donor, Tivortin® aspartate participates in the processes of energy supply of the body, reduces the activation and adhesion of leukocytes and platelets to the vascular endothelium, preventing the formation and development of atherosclerotic plaques, and is involved in the processes of fibrinogenolysis and spermatogenesis.
The drug has a moderate anabolic effect, stimulates the activity of the thymus gland, promotes insulin synthesis and regulates blood glucose levels during physical exertion, and helps correct acid-base balance.
Pharmacokinetics
Not studied.
Indication
In the complex therapy of ischemic heart disease, atherosclerosis of the heart and brain vessels, arterial hypertension, atherosclerosis of peripheral vessels; diabetic angiopathy; conditions after acute myocardial infarction and acute cerebrovascular accident; myocardiopathy, chronic heart failure; hypercholesterolemia; chronic obstructive pulmonary diseases, interstitial pneumonia, idiopathic pulmonary hypertension, chronic postembolic pulmonary hypertension, acute and chronic hepatitis of various etiologies; liver failure, hepatic encephalopathy caused by hyperammonemia; hypoxic and asthenic conditions; immunocorrection with decreased thymus function.
Contraindication
Hypersensitivity, severe renal impairment.
Interaction with other medicinal products and other types of interactions
When using arginine aspartate, it should be taken into account that the combined use of aminophylline with arginine may be accompanied by an increase in insulin levels in the blood; spironolactone with arginine - an increase in potassium levels in the blood.
Application features
It should be used with caution in cases of electrolyte imbalance, kidney disease. When using the drug, it is necessary to adhere to a balanced sleep and rest regimen, and to avoid alcohol, nicotine, and psychostimulants. If symptoms of asthenia increase while taking the drug, treatment should be discontinued.
Patients with hereditary fructose intolerance should not take the drug.
Use during pregnancy or breastfeeding
The drug penetrates the placenta, so it can be used during pregnancy only if the expected benefit to the mother outweighs the potential risk to the fetus.
There are no data on the use of the drug during breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Method of administration and doses
Use orally, take with meals. Adults with ischemic heart disease, atherosclerosis of the heart and brain vessels, atherosclerosis of peripheral vessels, diabetic angiopathy 5 ml (1 measuring spoon - 1 g of the drug) 3-8 times a day. With hypercholesterolemia, conditions after acute myocardial infarction and acute cerebrovascular accident, arterial hypertension - 5 ml 3-6 times a day. With chronic obstructive pulmonary diseases, interstitial pneumonia, idiopathic pulmonary hypertension, chronic postembolic pulmonary hypertension - 5 ml 3-6 times a day. Acute and chronic hepatitis of various etiologies, liver failure, hepatic encephalopathy caused by hyperammonemia - 5 ml 3-6 times a day. In hypoxic and asthenic conditions, immunocorrection with reduced thymus function, 5 ml 4-8 times a day. The maximum daily dose is 8 g. The duration of the course of treatment is 8-15 days; if necessary, the course of treatment is repeated.
Children
Do not use under 18 years of age.
Overdose
Symptoms: hypersensitivity reactions, hypoglycemic states.
Treatment. If these symptoms occur, the drug should be discontinued. Gastric lavage and sorbents are indicated. There is no antidote. Symptomatic therapy.
Adverse reactions
The drug contains excipients such as E216 and E218, which may cause allergic reactions (possibly delayed) and in some cases bronchospasm.
Expiration date
2 years.
The shelf life after opening the bottle is 14 days.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children. Do not freeze.
Incompatibility.
Information is missing.
Packaging
100 ml, 200 ml in a bottle; 1 bottle with a measuring spoon in a cardboard box; 5 ml, 10 ml in single-dose containers, 10 containers in a cardboard box.
Vacation category
Without a prescription.
Manufacturer/Applicant
LLC "Yuria-Pharm".
Location of the manufacturer and its business address/location of the applicant and/or the applicant's representative
Ukraine, 18030, Cherkasy, Verbovetskogo St., 108, tel. (044) 281-01-01.
